8-K Announcements
6Material company update
Apr 22, 2026·SEC
Material company update
Mar 10, 2026·SEC
Material company update
Mar 2, 2026·SEC
Elevance Health Inc.(ELV)Earnings, Financials & Key Ratios
ELV•NYSE•Insurance & Managed Care
$369.07
$80.15B mkt cap·14.7× P/E·Price updated May 6, 2026
AboutElevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.Show more
- Revenue$199.13B+12.6%
- Combined Ratio95.93%+1.0%
- Net Income$5.66B-5.3%
- Return on Equity13.25%-10.4%
- Medical Cost Ratio74.44%+3.2%
- Operating Margin4.07%-19.0%
- Net Margin2.84%-15.9%
- ROA4.75%-10.3%
- Equity / Assets36.24%+2.2%
- Book Value per Share198.49+11.6%
- Tangible BV/Share20.21+346.1%
- Debt/Equity0.75-4.4%
ELV Key Insights
Elevance Health Inc. (ELV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓15 consecutive years of dividend growth
- ✓Share count reduced 4.8% through buybacks
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ELV Price & Volume
Elevance Health Inc. (ELV) stock price & volume — 10-year historical chart
Loading chart...
ELV Growth Metrics
Elevance Health Inc. (ELV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years9.65%
5 Years10.32%
3 Years8.34%
TTM9.44%
Profit CAGR
10 Years8.26%
5 Years4.37%
3 Years-1.33%
TTM-11.39%
EPS CAGR
10 Years10.35%
5 Years6.92%
3 Years1.14%
TTM-8.27%
Return on Capital
10 Years9.79%
5 Years9.85%
3 Years9.25%
Last Year8.15%
ELV Recent Earnings
Elevance Health Inc. (ELV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
Apr 22, 2026EPS
$12.58
Est $11.03
+14.1%
Revenue
$49.5B
Est $48.2B
+2.7%
Q1 2026
Jan 28, 2026EPS
$3.33
Est $3.10
+7.4%
Revenue
$49.3B
Est $49.8B
-1.1%
Q4 2025
Oct 21, 2025EPS
$6.03
Est $4.93
+22.3%
Revenue
$50.7B
Est $49.4B
+2.7%
Q3 2025
Jul 17, 2025EPS
$8.84
Est $8.91
-0.8%
Revenue
$49.8B
Est $48.2B
+3.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 22, 2026 | $12.58vs $11.03+14.1% | $49.5Bvs $48.2B+2.7% |
| Q1 2026 | Jan 28, 2026 | $3.33vs $3.10+7.4% | $49.3Bvs $49.8B-1.1% |
| Q4 2025 | Oct 21, 2025 | $6.03vs $4.93+22.3% | $50.7Bvs $49.4B+2.7% |
| Q3 2025 | Jul 17, 2025 | $8.84vs $8.91-0.8% | $49.8Bvs $48.2B+3.3% |
Based on last 12 quarters of dataView full earnings history →
ELV Peer Comparison
Elevance Health Inc. (ELV) competitors in National Multi-Line Health Insurers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 UNH | 330.28B | 363.87 | 27.50 | 11.81% | 2.68% | 11.54% | 4.87% | 0.77 |
 CVS | 102.56B | 80.69 | 58.05 | 7.85% | 0.44% | 2.35% | 7.61% | 1.24 |
 CI | 72.68B | 275.66 | 12.43 | 11.26% | 2.26% | 15.08% | 11.54% | 0.75 |
 HUM | 28.76B | 239.53 | 24.34 | 10.06% | 0.82% | 6.17% | 1.3% | 0.73 |
 CNC | 26.15B | 52.97 | -3.89 | 19.44% | -3.25% | -28.6% | 16.52% | 0.94 |
 MOH | 10.01B | 192.17 | 21.54 | 11.75% | 0.42% | 4.44% | 0.97 | |
 OSCR | 4.71B | 17.94 | -10.62 | 27.5% | -3.79% | -45.19% | 22.49% | 0.44 |
 CLOV | 1.35B | 2.61 | -15.35 | 40.34% | -4.45% | -27.71% |
Compare ELV vs Peers
Elevance Health Inc. (ELV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ELV Income Statement
Elevance Health Inc. (ELV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.04B | 92.11B | 104.21B | 121.87B | 138.64B | 156.59B | 171.34B | 176.81B | 199.13B | 200.41B |
| Revenue Growth % | 5.96% | 2.29% | 13.15% | 16.94% | 13.76% | 12.95% | 9.42% | 3.19% | 12.62% | 9.44% |
| Medical Costs & Claims | 72.24B | 71.89B | 81.79B | 88.05B | 102.64B | 116.64B | 124.33B | 127.57B | 148.22B | 153.99B |
| Medical Cost Ratio % | 80.23% | 78.06% | 78.48% | 72.25% | 74.04% | 74.49% | 72.56% | 72.15% | 74.44% | 76.84% |
| Gross Profit | 17.8B▲ 0% | 20.21B▲ 13.5% | 22.43B▲ 11.0% | 33.82B▲ 50.8% | 35.99B▲ 6.4% | 39.95B▲ 11.0% | 47.01B▲ 17.7% | 49.24B▲ 4.8% | 50.9B▲ 3.4% | 46.43B▲ 0% |
| Gross Margin % | 19.77% | 21.94% | 21.52% | 27.75% | 25.96% | 25.51% | 27.44% | 27.85% | 25.56% | 23.16% |
| Gross Profit Growth % | -1.88% | 13.52% | 10.97% | 50.81% | 6.42% | 11% | 17.66% | 4.75% | 3.37% | - |
| Operating Expenses | 12.82B | 14.37B | 15.69B | 26.11B | 27.05B | 31.5B | 38.27B | 40.35B | 42.79B | 38.79B |
| OpEx / Revenue % | 14.24% | 15.61% | 15.06% | 21.43% | 19.51% | 20.12% | 22.33% | 22.82% | 21.49% | 19.36% |
| Depreciation & Amortization | 891M | 1.13B | 1.13B | 1.15B | 1.3B | 1.68B | 1.75B | 1.39B | 1.55B | 1.28B |
| Combined Ratio % | 94.46% | 93.66% | 93.54% | 93.67% | 93.55% | 94.6% | 94.9% | 94.97% | 95.93% | 96.19% |
| Operating Income | 4.99B▲ 0% | 5.84B▲ 17.1% | 6.73B▲ 15.4% | 7.71B▲ 14.5% | 8.95B▲ 16.0% | 8.45B▼ 5.5% | 8.74B▲ 3.5% | 8.89B▲ 1.6% | 8.11B▼ 8.7% | 7.63B▲ 0% |
| Operating Margin % | 5.54% | 6.34% | 6.46% | 6.33% | 6.45% | 5.4% | 5.1% | 5.03% | 4.07% | 3.81% |
| Operating Income Growth % | -8.01% | 17.09% | 15.35% | 14.53% | 16.02% | -5.53% | 3.48% | 1.64% | -8.73% | - |
| EBITDA | 5.88B | 6.97B | 7.87B | 8.87B | 10.25B | 10.13B | 10.49B | 10.28B | 9.66B | 8.92B |
| EBITDA Margin % | 6.53% | 7.57% | 7.55% | 7.27% | 7.39% | 6.47% | 6.12% | 5.81% | 4.85% | 4.45% |
| Interest Expense | 739M | 753M | 746M | 784M | 798M | 851M | 1.03B | 1.19B | 1.4B | 1.42B |
| Non-Operating Income | 282.4M | 16M | 2M | 689M | 223M | 0 | 0 | -201M | 0 | 0 |
| Pretax Income | 3.96B▲ 0% | 5.07B▲ 27.9% | 5.99B▲ 18.1% | 6.24B▲ 4.2% | 7.92B▲ 27.0% | 7.6B▼ 4.1% | 7.71B▲ 1.5% | 7.9B▲ 2.4% | 6.71B▼ 15.1% | 6.22B▲ 0% |
| Pretax Margin % | 4.4% | 5.5% | 5.74% | 5.12% | 5.72% | 4.85% | 4.5% | 4.47% | 3.37% | 3.1% |
| Income Tax | 121M | 1.32B | 1.18B | 1.67B | 1.83B | 1.71B | 1.72B | 1.93B | 1.05B | 980M |
| Effective Tax Rate % | 3.05% | 26.01% | 19.68% | 26.71% | 23.09% | 22.53% | 22.35% | 24.46% | 15.63% | 15.76% |
| Net Income | 3.84B▲ 0% | 3.75B▼ 2.4% | 4.81B▲ 28.2% | 4.57B▼ 4.9% | 6.1B▲ 33.5% | 5.89B▼ 3.4% | 5.99B▲ 1.6% | 5.98B▼ 0.1% | 5.66B▼ 5.3% | 5.24B▲ 0% |
| Net Margin % | 4.27% | 4.07% | 4.61% | 3.75% | 4.4% | 3.76% | 3.49% | 3.38% | 2.84% | 2.62% |
| Net Income Growth % | 55.59% | -2.41% | 28.19% | -4.89% | 33.51% | -3.44% | 1.58% | -0.12% | -5.32% | -11.39% |
| EPS (Diluted) | 14.35▲ 0% | 14.19▼ 1.1% | 18.47▲ 30.2% | 17.98▼ 2.7% | 24.73▲ 37.5% | 24.28▼ 1.8% | 25.22▲ 3.9% | 25.68▲ 1.8% | 25.12▼ 2.2% | 23.79▲ 0% |
| EPS Growth % | 55.81% | -1.11% | 30.16% | -2.65% | 37.54% | -1.82% | 3.87% | 1.82% | -2.18% | -8.27% |
| EPS (Basic) | 14.70 | 14.53 | 18.81 | 18.23 | 25.25 | 24.56 | 25.38 | 25.81 | 25.18 | - |
| Diluted Shares Outstanding | 267.8M | 254.3M | 260.3M | 254.3M | 246.8M | 242.8M | 237.4M | 232.9M | 221.8M | 220.4M |
ELV Balance Sheet
Elevance Health Inc. (ELV) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 71.46B | 72.47B | 78.25B | 88.28B | 97.46B | 102.75B | 108.93B | 116.89B | 121.49B | 125.83B |
| Asset Growth % | 7.64% | 1.41% | 7.98% | 12.81% | 10.4% | 5.43% | 6.01% | 7.31% | 3.94% | 22.3% |
| Total Investment Assets | 24.93B | 22.45B | 25.46B | 29.84B | 34.01B | 33.34B | 36.83B | 37.18B | 38.58B | 4M |
| Long-Term Investments | 24.93B | 22.45B | 25.46B | 29.84B | 34.01B | 33.34B | 36.83B | 37.18B | 38.58B | 127.75B |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25.91B |
| Total Current Assets | 9.79B | 10.68B | 12.52B | 13.87B | 14.57B | 19.13B | 18.99B | 21.34B | 24.73B | 67.03B |
| Cash & Equivalents | 3.61B | 3.93B | 4.94B | 5.74B | 4.88B | 7.39B | 6.53B | 8.29B | 9.49B | 9.66B |
| Receivables | 6.18B | 6.74B | 7.58B | 8.13B | 9.69B | 11.75B | 12.46B | 13.05B | 15.23B | 68.6B |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.68B |
| Goodwill & Intangibles | 27.6B | 29.51B | 29.17B | 31.1B | 34.84B | 34.7B | 35.59B | 40.37B | 39.54B | 158.61B |
| Goodwill | 19.23B | 20.5B | 20.5B | 21.69B | 24.23B | 24.38B | 25.32B | 28.28B | 28.34B | 28.34B |
| Intangible Assets | 8.37B | 9.01B | 8.67B | 9.4B | 10.62B | 10.31B | 10.27B | 12.09B | 11.2B | 11.09B |
| PP&E (Net) | 2.17B | 2.73B | 3.71B | 4.13B | 4.55B | 4.92B | 4.94B | 5.22B | 5.13B | 4.66B |
| Other Assets | 6.04B | 6.2B | 6.59B | 7.68B | 9.39B | 10.53B | 12.36B | 12.57B | 13.21B | 2.58B |
| Total Liabilities | 44.96B | 43.93B | 46.53B | 55.08B | 61.33B | 66.42B | 69.52B | 75.46B | 77.47B | 81.78B |
| Total Debt | 19.93B | 19.21B | 21.21B | 21.84B | 24.89B | 25.8B | 26.65B | 32.7B | 33.23B | 31.84B |
| Net Debt | 16.32B | 15.28B | 16.27B | 16.1B | 20.01B | 18.41B | 20.13B | 24.41B | 23.74B | 22.18B |
| Long-Term Debt | 17.38B | 17.22B | 18.27B | 20.18B | 22.02B | 23.1B | 23.93B | 29.88B | 31.33B | 31.12B |
| Short-Term Debt | 2.55B | 1.99B | 2.46B | 810M | 2.01B | 1.95B | 2.04B | 2.17B | 1.38B | 724M |
| Total Current Liabilities | 10.54B | 9.45B | 11.3B | 12.17B | 15.53B | 18.65B | 19.55B | 19.42B | 19.96B | 45.31B |
| Accounts Payable | 7.99B | 7.45B | 8.84B | 11.36B | 13.52B | 15.6B | 16.11B | 15.75B | 17.08B | 6.21B |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 1.11B | 1.4B | 1.51B | 1.49B | 1.76B |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36.62B |
| Deferred Taxes | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 8.22B |
| Other Liabilities | 13.53B | 13.5B | 12.43B | 16.94B | 18.96B | 20.79B | 23.39B | 23.36B | 23.55B | 3.57B |
| Total Equity | 26.5B▲ 0% | 28.54B▲ 7.7% | 31.73B▲ 11.2% | 33.2B▲ 4.6% | 36.13B▲ 8.8% | 36.33B▲ 0.6% | 39.41B▲ 8.5% | 41.43B▲ 5.1% | 44.03B▲ 6.3% | 44.04B▲ 0% |
| Equity Growth % | 5.59% | 7.69% | 11.17% | 4.64% | 8.82% | 0.56% | 8.46% | 5.13% | 6.28% | 13.75% |
| Shareholders Equity | 26.5B | 28.54B | 31.73B | 33.2B | 36.06B | 36.24B | 39.31B | 41.31B | 43.88B | 43.9B |
| Minority Interest | 0 | 0 | 0 | 0 | 68M | 87M | 99M | 111M | 144M | 140M |
| Retained Earnings | 18.05B | 19.99B | 22.57B | 23.8B | 27.09B | 29.65B | 31.75B | 33.55B | 35.39B | 35.8B |
| Common Stock | 2.6M | 3M | 3M | 3M | 2M | 2M | 2M | 2M | 2M | 2M |
| Accumulated OCI | -101.5M | -986M | -296M | 150M | -178M | -2.49B | -1.31B | -1.15B | -451M | -741M |
| Return on Equity (ROE) | 14.89% | 13.63% | 15.95% | 14.08% | 17.61% | 16.27% | 15.81% | 14.8% | 13.25% | 11.92% |
| Return on Assets (ROA) | 5.58% | 5.21% | 6.38% | 5.49% | 6.57% | 5.89% | 5.66% | 5.3% | 4.75% | 4.26% |
| Equity / Assets | 37.09% | 39.38% | 40.54% | 37.61% | 37.07% | 35.36% | 36.18% | 35.44% | 36.24% | 35% |
| Debt / Equity | 0.75x | 0.67x | 0.67x | 0.66x | 0.69x | 0.71x | 0.68x | 0.79x | 0.75x | 0.75x |
| Book Value per Share | 98.97 | 112.23 | 121.89 | 130.55 | 146.39 | 149.63 | 165.99 | 177.87 | 198.49 | 199.83 |
| Tangible BV per Share | -4.10 | -3.81 | 9.81 | 8.27 | 5.21 | 6.72 | 16.07 | 4.53 | 20.21 | 20.91 |
ELV Cash Flow Statement
Elevance Health Inc. (ELV) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 4.18B | 3.83B | 6.06B | 10.69B | 8.36B | 8.4B | 8.06B | 5.81B | 4.29B | 4.29B |
| Operating CF Growth % | 30.59% | -8.55% | 58.37% | 76.34% | -21.74% | 0.42% | -4.02% | -27.95% | -26.14% | 539.76% |
| Operating CF / Revenue % | 4.65% | 4.16% | 5.82% | 8.77% | 6.03% | 5.36% | 4.7% | 3.28% | 2.15% | 2.14% |
| Net Income | 3.84B | 3.75B | 4.81B | 4.57B | 6.09B | 6.02B | 5.99B | 5.97B | 5.66B | 5.24B |
| Depreciation & Amortization | 890.4M | 1.13B | 1.13B | 1.15B | 1.3B | 1.68B | 1.75B | 1.39B | 1.55B | 1.53B |
| Stock-Based Compensation | 169.6M | 226M | 294M | 283M | 255M | 264M | 289M | 191M | 276M | 250M |
| Deferred Taxes | -1.27B | 91M | 81M | -540M | 173M | -76M | -602M | -374M | -279M | -379M |
| Other Non-Cash Items | 186.2M | 235M | -62M | 16M | -245M | 264M | 1.18B | 346M | 363M | 1.41B |
| Working Capital Changes | 367.9M | -1.6B | -192M | 5.2B | 784M | 253M | -535M | -1.72B | -3.28B | -436M |
| Cash from Investing | -5.08B | -1.26B | -2.79B | -7.32B | -9.64B | -4.56B | -5.57B | -5.17B | -1.34B | -3.09B |
| Capital Expenditures | -790.2M | -1.21B | -1.08B | -1.02B | -1.09B | -1.15B | -1.3B | -1.26B | -1.12B | -1.16B |
| Acquisitions | -2.08B | -1.76B | 0 | -1.98B | -3.48B | -649M | -1.55B | -4.45B | 88M | 89M |
| Purchase of Investments | -16.37B | -9.67B | -22.95B | -19.49B | -18.67B | -24.95B | -16.24B | -17.99B | -15.03B | -15.8B |
| Sale/Maturity of Investments | 13.53B | 11.6B | 21.04B | 16.06B | 14.61B | 22.61B | 13.54B | 18.57B | 15.1B | 14.17B |
| Other Investing | 636.4M | -220M | 204M | -894M | -1.02B | -421M | -24M | -51M | -385M | -392M |
| Cash from Financing | 426.9M | -2.24B | -2.27B | -2.57B | 423M | -1.32B | -3.35B | 1.19B | -1.74B | -2.34B |
| Dividends Paid | -704.9M | -776M | -818M | -954M | -1.1B | -1.23B | -1.4B | -1.51B | -1.53B | -1.52B |
| Share Repurchases | -2B | -1.69B | -1.7B | -2.7B | -1.9B | -2.32B | -2.68B | -2.9B | -2.6B | -2.85B |
| Stock Issued | 0 | 1.25B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37M |
| Debt Issuance (Net) | 1000K | -1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 2M |
| Other Financing | -820.7M | -355M | -271M | 899M | 1.08B | 432M | -17M | 39M | 69M | -398M |
| Net Change in Cash | -466.4M▲ 0% | 325M▲ 169.7% | 1B▲ 208.6% | 804M▼ 19.8% | -861M▼ 207.1% | 2.51B▲ 391.2% | -861M▼ 134.3% | 1.76B▲ 304.6% | 1.2B▼ 31.7% | 2.16B▲ 0% |
| Exchange Rate Effect | 4.3M | -2M | 0 | 7M | -10M | -14M | -1M | -72M | -5M | -15M |
| Cash at Beginning | 4.08B | 3.61B | 3.93B | 4.94B | 5.74B | 4.88B | 7.39B | 6.53B | 8.29B | 9.49B |
| Cash at End | 3.61B | 3.93B | 4.94B | 5.74B | 4.88B | 7.39B | 6.53B | 8.29B | 9.49B | 9.66B |
| Free Cash Flow | 3.39B▲ 0% | 2.62B▼ 22.8% | 4.98B▲ 90.3% | 9.67B▲ 94.0% | 7.28B▼ 24.7% | 7.25B▼ 0.4% | 6.76B▼ 6.7% | 4.55B▼ 32.7% | 3.17B▼ 30.3% | 6.45B▲ 0% |
| FCF Growth % | 29.52% | -22.85% | 90.3% | 93.96% | -24.72% | -0.41% | -6.65% | -32.71% | -30.27% | 75.56% |
| FCF Margin % | 3.77% | 2.84% | 4.78% | 7.93% | 5.25% | 4.63% | 3.95% | 2.57% | 1.59% | 3.22% |
| FCF per Share | 12.68 | 10.3 | 19.15 | 38.01 | 29.49 | 29.85 | 28.5 | 19.54 | 14.31 | 14.31 |
ELV Key Ratios
Elevance Health Inc. (ELV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Combined Ratio | 94.46% | 93.66% | 93.54% | 93.67% | 93.55% | 94.6% | 94.9% | 94.97% | 95.93% | 96.19% |
| Medical Cost Ratio | 80.23% | 78.06% | 78.48% | 72.25% | 74.04% | 74.49% | 72.56% | 72.15% | 74.44% | 76.84% |
| Return on Equity (ROE) | 14.89% | 13.63% | 15.95% | 14.08% | 17.61% | 16.27% | 15.81% | 14.8% | 13.25% | 11.92% |
| Return on Assets (ROA) | 5.58% | 5.21% | 6.38% | 5.49% | 6.57% | 5.89% | 5.66% | 5.3% | 4.75% | 4.26% |
| Equity / Assets | 37.09% | 39.38% | 40.54% | 37.61% | 37.07% | 35.36% | 36.18% | 35.44% | 36.24% | 35% |
| Book Value / Share | 98.97 | 112.23 | 121.89 | 130.55 | 146.39 | 149.63 | 165.99 | 177.87 | 198.49 | 199.83 |
| Debt / Equity | 0.75x | 0.67x | 0.67x | 0.66x | 0.69x | 0.71x | 0.68x | 0.79x | 0.75x | 0.75x |
| Revenue Growth | 5.96% | 2.29% | 13.15% | 16.94% | 13.76% | 12.95% | 9.42% | 3.19% | 12.62% | 9.44% |
ELV SEC Filings & Documents
Elevance Health Inc. (ELV) SEC filings — annual & quarterly reports (10-K, 10-Q)
ELV Frequently Asked Questions
Elevance Health Inc. (ELV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Elevance Health Inc. (ELV) grew revenue by 12.6% over the past year. This is steady growth.
Yes, Elevance Health Inc. (ELV) is profitable, generating $5.24B in net income for fiscal year 2025 (2.8% net margin).
Dividend & Returns
Yes, Elevance Health Inc. (ELV) pays a dividend with a yield of 1.87%. This makes it attractive for income-focused investors.
Elevance Health Inc. (ELV) has a return on equity (ROE) of 13.3%. This is reasonable for most industries.
Industry Metrics
Elevance Health Inc. (ELV) has a combined ratio of 95.9%. A ratio below 100% indicates underwriting profitability.
Explore More ELV
Elevance Health Inc. (ELV) financial analysis — history, returns, DCA and operating performance tools
Full ELV Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates